Management of severe fibrocystic disease of the breast with leuprolide acetate.
Symptoms of severe fibrocystic disease of the breast were successfully ameliorated in two patients as a result of treatment with daily subcutaneous LA without adverse effects. A state of drug-induced hypogonadotropic hypogonadism appears to be responsible for the clinical effect and is further suggestive of the hormonal dependence of this common disorder.
Richardson
M R
MR
Department of Obstetrics and Gynecology, Truman Medical Center, Kansas City, Missouri 64108.
Njemanze
J
J
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005348:Fibrocystic Breast Disease / Q000188:drug therapy*; D007987:Gonadotropin-Releasing Hormone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide
D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide